EMA’s CHMP recommends approval for AbbVie’s axial spondyloarthritis therapy
Rinvoq, which is discovered and developed by AbbVie scientists, is a selective JAK inhibitor that is being studied in many immune-mediated inflammatory diseases. The regulator has recommended the